EUVIMEDEUVIMED entdecken
Leserbrief

Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non‐gemfibrozil fibrate trials

Takahito Doi, Anne Langsted iD, Børge G Nordestgaard iD

Journal of Internal Medicine · 2024

DOI: 10.1111/joim.13771 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Internal Medicine, 2024. Verfasst von Takahito Doi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark. Hauptthemen laut MEDLINE: Gemfibrozil, Cholesterol. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Region Hovedstaden, Japan Society for Science Promotion Postdoctral Fellowship for Research Abroad.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Table S1. Absolute changes of lipid traits in PROMINENT, ACCORD, FIELD, BIP, VA-HIT, and HHS. Table S2. Comparison of different gemfibrozil and non-gemfibrozil fibrate trials and CGPS mimicking corresponding trial. Figure S1. Comparison of gemfibrozil and non-gemfibrozil fibrate trials and corresponding Copenhagen General Population Study mimicking trials using calculated LDL cholesterol and remnant cholesterol by the Martin-Hopkins equation. Figure S2. Comparison of gemfibrozil and non-gemfibrozil fibrate trials and corresponding Copenhagen General Population Study mimicking trials using non-HDL cholesterol. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GemfibrozilCholesterolHumansCholesterol, LDLFibric AcidsHypolipidemic AgentsTriglyceridesCholesterol, HDLLipoproteins, LDL

Stichwörter der Autor:innen

coronary diseaselipidsmyocardial infarctionstroketriglycerides‐rich lipoproteinsvery low‐density lipoproteins

Substanzen

GemfibrozilCholesterol, LDLFibric AcidsCholesterolHypolipidemic AgentsTriglyceridesCholesterol, HDLLipoproteins, LDL

Autor:innen und Institutionen

  • Department of Clinical Biochemistry, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark.
  • The Copenhagen General Population Study, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark.
  • Faculty of Health and Medical Sciences, Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Anne Langsted, Børge G Nordestgaard

Förderung

  • Region Hovedstaden
  • Japan Society for Science Promotion Postdoctral Fellowship for Research Abroad

Zitieren

APA

Doi, T., Langsted, A., & Nordestgaard, B. G. (2024). Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non‐gemfibrozil fibrate trials. Journal of Internal Medicine. https://doi.org/10.1111/joim.13771

Vancouver

Doi T, Langsted A, Nordestgaard BG. Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non‐gemfibrozil fibrate trials. Journal of Internal Medicine. 2024. doi:10.1111/joim.13771

BibTeX
@article{Doi2024,
  author = {Doi, Takahito and Langsted, Anne and Nordestgaard, Børge G},
  title = {Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non‐gemfibrozil fibrate trials},
  journal = {Journal of Internal Medicine},
  year = {2024},
  doi = {10.1111/joim.13771}
}
Kostenlos starten →